Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open in the red
Thu, 9 Jan 09:30 am

The major Asian stock markets have opened the day in the red with stock markets in Singapore (down 0.2%) and Japan (down 1.4%) leading the losses. The Indian share market indices have also opened the day on a weak note. The sectoral indices have opened mixed with the stocks in the power and software space leading the gains. However, the stocks in banking and FMCG space were leading the losses.

The Sensex today is down by around 33 points (0.2%) while the NSE-Nifty is down by around 14 points (0.2%). Mid and small cap stocks have opened in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.3% and 0.4% respectively. The rupee is currently trading at Rs 62.21 to the US dollar.

Steel stocks have opened the day mainly in the red with Tayo Rolls Ltd and Jindal Steel Ltd leading the losses. As per a leading financial daily, Tata Steel Ltd has bagged a two-year contract to supply over 2 lac tonnes of highly wear-resistant rail tracks to a French rail operator SNCF. Tata Steel's Europe unit will supply the majority of SNCF's rail requirements from its plant at Hayange in northern France. Tata Steel had made a €35 m investment in 2011 in Hayange mill that allowed it to produce 108m lengths of rail that SNCF will use throughout France's standard and high-speed networks. The Hayange rolling mill sources steel from Tata Steel's Scunthorpe steelworks in the UK. The new order is in addition to a previous contract with SNCF.

Indian Pharma stocks have opened the day on a mixed note with IPCA Labs and Cadila Healthcare Ltd leading the gains. However, Dishman Pharma Ltd and JB Chemicals Ltd were facing selling pressure. As per a leading financial daily, the Government has decided against a blanket ban on the incorporation of a 'non-compete' clause if an Indian pharma company is acquired by a foreign drug company. Earlier, the ban was mooted by the Department of Industrial Policy and Promotion (DIPP) as a safeguard to ensure acquisition of Indian pharma companies does not lead to shortage of critical drugs. However, the Government has decided to continue with the existing policy with the condition that such a clause could be allowed by Foreign Investment Promotion Board (FIPB) in special circumstances.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.